Loading…
Prothena Corp Public Ltd Co
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in PRTA.
▼ -85.0% over 5Y.
today you would have $116.38▼ -88.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 14 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $9.55 | $13.85 | $36.34 | $60.25 | $49.40 | $12.01 | $15.83 | $10.30 | $37.49 | $49.19 | $68.11 | $20.76 | $26.52 | $7.33 | |
| P/E | — | — | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PBYIPuma Biotechnology Inc | $9.28 | 18.2x | 3.4x | — | 21.97% | $479.03M |
| EVMNEvommune, Inc. | $13.23 | — | 1.7x | — | -52.11% | $480.14M |
| NRCNRC Health | $21.85 | 91.0x | 73.8x | 2.93% | 42.03% | $483.31M |
| CLPTClearPoint Neuro, Inc. | $15.55 |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Company description provided by Yahoo Finance.
| 35.8x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 55.9x | 53.1x | 5.5x | 21.4x | 58.8x | 11.5x | 563.0x | 776.2x | 429.9x | 52.5x | 1633.2x | 1455.4x | 11.2x | 859.3x | 48.8x |
| P/B | 3.0x | 1.8x | 1.5x | 3.5x | 5.1x | 4.9x | 2.6x | 2.3x | 1.3x | 3.5x | 4.7x | 6.5x | 2.0x | 3.4x | 1.0x |
| EPS | -$4.53 | -$2.27 | -$2.76 | -$2.47 | $1.38 | -$2.78 | -$1.95 | -$3.93 | -$4.07 | -$4.66 | -$2.66 | -$0.29 | -$2.20 | -$2.84 |
| Profit margin | -2039.27% | -2520.57% | -90.49% | -160.91% | -216.95% | 33.39% | -13029.78% | -9542.63% | -16297.91% | -556.84% | -15176.11% | -5016.30% | -14.06% | -6064.50% | -1557.98% |
| ROE | -27.33% | -87.03% | -25.12% | -26.19% | -18.80% | 14.37% | -60.40% | -28.46% | -48.19% | -37.63% | -43.82% | -22.35% | -2.47% | -23.66% | -32.74% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 44.1x |
| — |
| -226.52% |
| $474.34M |
| SRTAStrata Critical Medical, Inc. | $5.34 | — | 1.7x | — | -9.22% | $472.41M |
| SGHTSight Sciences, Inc. | $8.50 | — | 8.8x | — | -48.42% | $468.25M |